Breadcrumb

[G19-06] Trametinib (melanoma) - Addendum to Commission A18-60

Overview

Overview

Commission: Commission awarded on 2019-02-11 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Health Economics
Current document:PDF Addendum to Commission A18-60  [PDF, 131 kB] (German version) Further documents
Note:

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

Contact address:to the contact form
Linked projects: [A18-60] Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2019-03-22 Addendum to Commission A18-60 (German version) 131 kBPDFdownload file

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close